Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes.

Diseases resulting from infection by group A streptococcus (GAS) are an increasing burden on global health. A novel vaccine was developed targeting infection by Streptococcus pyogenes. The vaccine incorporates a recombinant fusion protein antigen (SpeAB) which was engineered by combining inactive mutant forms of streptococcal pyrogenic exotoxin A (SpeA) and streptococcal pyrogenic exotoxin B (SpeB) from S. pyogenes. A rational, scientific approach to vaccine development was utilized to determine optimal formulation conditions with aluminum adjuvants. Investigations of the pH stability profile of SpeAB concluded the antigen was most stable near pH 8. Incorporation of the stabilizers sucrose and mannitol significantly enhanced the stability of the antigen. Vaccines were formulated in which most of the SpeAB was adsorbed to the adjuvant or remained in solution. A SpeAB vaccine formulation, stabilized with sucrose, in which the antigen remains adsorbed to the aluminum adjuvant retained the greatest potency as determined by evaluation of neutralizing antibody responses in mice. This vaccine has great potential to provide a safe and effective method for prevention of GAS disease.

[1]  J. Musser,et al.  6 The revival of group A streptococcal diseases, with a commentary on staphylococcal toxic shock syndrome , 1998 .

[2]  João André Carriço,et al.  Scarlet Fever Is Caused By a Limited Number of Streptococcus pyogenes Lineages and Is Associated with the Exotoxin Genes ssa, speA and speC , 2014, The Pediatric infectious disease journal.

[3]  A. Norrby-Teglund,et al.  Correlation between serum TNF alpha and IL6 levels and severity of group A streptococcal infections. , 1995, Scandinavian journal of infectious diseases.

[4]  I. Tatsuno,et al.  Partial loss of CovS function in Streptococcus pyogenes causes severe invasive disease , 2013, BMC Research Notes.

[5]  Anna Sokolovska,et al.  Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. , 2007, Vaccine.

[6]  H. HogenEsch,et al.  Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. , 2007, Vaccine.

[7]  S. Skrede,et al.  emm gene diversity, superantigen gene profiles and presence of SlaA among clinical isolates of group A, C and G streptococci from western Norway , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  S. Hem,et al.  Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. , 2009, Vaccine.

[9]  Ariel Rodríguez,et al.  High Levels of Diversity Uncovered in a Widespread Nominal Taxon: Continental Phylogeography of the Neotropical Tree Frog Dendropsophus minutus , 2014, PloS one.

[10]  J. Musser,et al.  Expression and Characterization of Group AStreptococcus Extracellular Cysteine Protease Recombinant Mutant Proteins and Documentation of Seroconversion during Human Invasive Disease Episodes , 1998, Infection and Immunity.

[11]  J. Lee,et al.  The stabilization of proteins by sucrose. , 1981, The Journal of biological chemistry.

[12]  R. Geahlen,et al.  Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. , 2005, Vaccine.

[13]  D. Stevens,et al.  Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. , 1996, The Journal of infectious diseases.

[14]  L. Peek,et al.  A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. , 2006, Vaccine.

[15]  A. Podbielski,et al.  The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin‐binding and cysteine protease activity , 2001, Molecular microbiology.

[16]  P. Trieu-Cuot,et al.  Invasive group A streptococcal infections in adults, France (2006-2010). , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  Yen-Hsu Chen,et al.  Emergence of Streptococcus pyogenes emm102 Causing Toxic Shock Syndrome in Southern Taiwan during 2005–2012 , 2013, PloS one.

[18]  R. Davis,et al.  Association Between Streptococcal Infection and Obsessive-Compulsive Disorder, Tourette's Syndrome, and Tic Disorder , 2005, Pediatrics.

[19]  M. A. Olson,et al.  Bacterial superantigens in human disease: structure, function and diversity. , 1995, Trends in microbiology.

[20]  D. Stevens.  Streptococcal toxic shock syndrome associated with necrotizing fasciitis. , 2000, Annual review of medicine.

[21]  P. Mathur,et al.  Outbreak of Streptococcus pyogenes emm type 58 in a high dependency unit of a level-1 trauma center of India , 2014, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[22]  Garry L. Morefield,et al.  A Rational, Systematic Approach for the Development of Vaccine Formulations , 2011, The AAPS Journal.

[23]  J. Musser,et al.  A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. , 1993, Microbial pathogenesis.

[24]  A. Mack.  Streptococcal Upper Respiratory Tract Infections and Exacerbations of Tic and Obsessive-Compulsive Symptoms: A Prospective Longitudinal Study , 2012 .

[25]  F. Regnier,et al.  Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. , 1995, Vaccine.

[26]  W. Graninger,et al.  Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002. , 2004, International journal of antimicrobial agents.

[27]  R. Lütticken,et al.  High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  R. Ulrich.  Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock , 2008, Journal of immune based therapies and vaccines.

[29]  J. White,et al.  Predicting the adsorption of proteins by aluminium-containing adjuvants. , 1991, Vaccine.

[30]  A. Olsén,et al.  Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease. , 2004, The Journal of infectious diseases.

[31]  L. Peek,et al.  A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. , 2007, Journal of pharmaceutical sciences.